Effect of a Multi Strain Probiotic on the Gut Microbiota
NCT ID: NCT04554641
Last Updated: 2021-02-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
48 participants
INTERVENTIONAL
2019-11-01
2021-02-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Bio-Kult Advanced is a live bacteria Food supplement that contains 14 different bacteria cultures. The effect of Bio-Kult Advanced on gut bacteria is unknown, therefore, the aim
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective Tolerability Assessment of a Probiotic Dietary Supplement
NCT04044144
The Impact of Probiotic Supplementation on Antibiotic Induced Changes in Gastrointestinal Function And/or Faecal Microbiota Composition
NCT05355571
Effect of a Nutritional Supplement on Gut Microbiota in Adults
NCT06611215
Effects of a Probiotic on Aspects of Mental Wellness
NCT05905679
Effect of Probiotic on Gut Microbiome and Bacterial Translocation in Healthy Asian Volunteers
NCT05083572
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Bio-Kult Advanced (BKA) is a 14 strain live bacteria supplement containing a Minimum 2 billion live microorganisms per capsule (2x109 CFU/capsule), equivalent to 10 billion live microorganisms per gram (1x1010 CFU/gram). A randomised controlled trial of Bio-Kult Advanced in the management of diarrhoea predominant IBS demonstrated significant improvement in gastrointestinal (GI) symptoms and was well tolerated by participants. Another randomised controlled trial of Bio-Kult Advanced, in participants with episodic and chronic migraine sufferers, demonstrated significant improvement in frequency and severity of migraines compared to placebo. This clinical effectiveness across various conditions, suggest that bacterial strains in Bio-Kult could have an effect on the gastrointestinal flora, however data has yet to be collected that explores the effect of Bio-Kult on the microbiome. The aim of this study is to therefore investigate the effect of Bio-Kult Advanced, on the composition of the gut microbiota in healthy adults.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BioKult Advanced
This is a single arm study, all participants will take Bio-kult Advanced for 56 days (+/- 2days). Participants will be required to take 4 capsules daily.
Fasted breath samples
Participants will provide fasted breath samples pre and post Bio-Kult Advanced.
Daily Diary
Monitoring stool form, consistency and frequency on a daily basis.
Stool sample
Participants will provide stool sample pre and post Bio-kult Advanced.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fasted breath samples
Participants will provide fasted breath samples pre and post Bio-Kult Advanced.
Daily Diary
Monitoring stool form, consistency and frequency on a daily basis.
Stool sample
Participants will provide stool sample pre and post Bio-kult Advanced.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No significant medical diagnosis (healthy individuals)
* Not on regular prescription medicines
* No selective/restricted diets (e.g. vegan, low FODMAP)
* Body Mass Index of 18.50-29.99 kg/m2
* Participant able to understand the participant information sheet in English and provide informed consent
Exclusion Criteria
* Prior abdominal surgery (e.g. appendectomy, bariatric surgery )
* Migraine as based on migraine definition by ICHD 2019:
* A minimum of five attacks (in absolute terms) fulfilling criteria:
* Duration 4 - 72 hours
* At least two of the following:
* unilateral location
* pulsating character
* moderate or severe pain intensity
* aggravation by routine physical activity
* Presence of nausea/vomiting OR photophobia/phonophobia during headache
* Ongoing therapy with medication known to affect the gut microbiome:
* Antibiotics used in the last 8 weeks
* Proton pump inhibitors used in the last 8 weeks
* Antidepressants in the last 8 weeks
* Regular use of laxatives or anti-diarrheal medications
* Alcohol consumption \>14 units per week
* Pregnancy or breastfeeding
* Vegan and other selective diets, use of diet replacements (e.g. Huel)
* Regular consumption of probiotics, prebiotics, fibre supplements or any use of probiotics in 2 months prior enrolment
* Unwillingness to exclude other probiotic products from diet during the study period
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ADM Protexin
INDUSTRY
The Functional Gut Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr Anthony Hobson
Consultant Clinical Scientist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anthony Hobson
Role: PRINCIPAL_INVESTIGATOR
The Functional Gut Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Functional Gut Clinic
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FGC-19-003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.